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Sweet dreams: how mini-invasive surgery tackles obstructive sleep apnea {#sec1.1}
-----------------------------------------------------------------------

"He who sleeps does not sin", claims a medieval mock syllogism, yet more dangers than one could expect linger in Morpheus\' arms. Proof that the bed is not necessarily a safe harbor is the panel of sleep disordered breathing (SDB) syndromes, ranging from simple snoring to obstructive sleep apnea (OSA), which consists in the complete or partial obstruction of the airways during sleep [@bib1]. It is normal for the overall muscle tone of the body to decrease during sleep, however, in some cases this can lead to the collapse of the soft tissues that compose the throat and airways. As a consequence, breathing is repeatedly reduced or paused for up to 40 s, causing depletion in blood oxygen saturation {Rochester:MkNi0iPx}. OAS can be transient in the context of upper respiratory infections causing the swelling of various tissues in the throat, or chronic. The latter is most common in middle-aged overweight individuals and twice as frequent in males (2--4%) than females. Many factors can contribute to the development of the syndrome, including craniofacial abnormalities and excessive bulk of soft tissue but also problems with the neurologic control of the upper airway musculature [@bib2].

The severity of the possible health repercussions of chronic OAS is commonly underestimated. OAS leads to serious daytime sleepiness, which impacts on working abilities, accidents due to lack of attention and a reduction of overall life quality, but increases also the risk for inner ear diseases as well as for hypertension and cardiovascular diseases, including myocardial infarction [@bib1] and eventually even for dementia [@bib3].

Continuous positive airway pressure (CPAP) is the standard first line of treatment for OAS [@bib4]. Patients wear a facemask by night through which a ventilator continuously applies light air pressure to keep the airways open. Other than the inevitable discomfort generated by the device, CPAP is not always efficient, leaving usually only surgery as an alternative treatment [@bib4]. Given the multifactorial etiology of OAS and the complex architecture of the human airways, this comprises in reality a multitude of possible interventions that have to be carefully selected, eventually combined and ultimately backed up with additional treatment methods in order to provide a long-term cure.

On these grounds, Li et al. update us in their comprehensive review article on the current state of the art in decision-making between CPAP and surgery but also surgery procedure types and finally stress the importance of postoperative integrated treatment [@bib5]. Concerning the decision-making between CPAP and surgery, the authors emphasize on the importance of distinguishing obstruction from collapse, as the first one evinces clear anatomical deformities that can be corrected surgically, while collapse mostly indicates neurological issues rather palliated by CPAP, without omitting all the exceptions and hybrid conditions.

Subsequently, the review takes the reader through the many different types of surgery, clearly stating for which precise pathological background they are the most appropriate. It becomes clear that over the recent years, much effort towards mini-invasiveness has been made as to preserve pharyngeal function. Intra-pharyngeal surgery for example has transited from blunt excision to a differential treatment of each tissue, such as ablation of adipose tissue, muscle suspension and mucosa preservation. Other recently developed techniques comprise mini-invasive septoturbinoplasty (MIST) as a form of nasal surgery and the use of the suspension technique as a way to minimize soft palate excision during uvulopalatopharyngoplasty.

Ultimately, the outcomes of the surgery are significantly enhanced by postoperative integrated treatment, such as the re-education and strengthening of the muscles and respiration training *via* oropharyngeal myofunctional therapy, positional therapy as to favor lateral sleep, weight loss and cognitive behavior therapy meant to re-acquire a healthy circadian rhythm.

All in all, it is very clear that OSA is a complex condition whose many forms and origins necessitate a thorough and precise preliminary analysis and a tailored strategy both for surgical correction and additional measures in order to maximize the benefit of the latter \[[Fig. 1](#fig1){ref-type="fig"}\].Fig. 1The complex task of treating obstructive sleep apnea (OSA). OSA is a multifactorial disease with severe possible consequences on health and life quality. Treatment success depends heavily on the precise identification of the anatomical origin of the problem, the tailored choice of intervention and the thorough backing-up of surgery by postoperative integrated treatments. At the surgery level, the recent trend is towards minimal invasiveness and a maximal preservation of pharyngeal function.Fig. 1
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Automated hematology has more than one string to its bow {#sec2.1}
--------------------------------------------------------

Although modern automated hematology analyzers are nowadays part and parcel of any hematology laboratory, they are mainly used only for cell counts and differential leukocyte analysis, despite the fact that most machines allow for the acquisition of way more parameters. Habit, lack of information about the full potential of the devices and skewed trust between well-trained hematologists and machines might be at fault [@bib6]. Among the available additional features are for example is the reticulocyte hemoglobin content (CHr), a good indicator for iron deficiency. As for leukocytes, a multitude of characteristics such as electrical impedance, radiofrequency conductivity, volume, conductivity and scatter (VCS) of up to 10^5^ cells in a few seconds can be obtained [@bib6]. Various combinations have already been suggested to serve the detection of viral, bacterial and parasitic infections, sepsis, or malignant hematological conditions [@bib7], [@bib8]. Patients with acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) for instance were shown to display distinct characteristic VCS profiles [@bib9].

In the present issue, Gaspar et al. propose to further exploit the technology\'s potential and investigate if the obtained data on leukocyte size and structure could be used to tell reactive from neoplastic cellular proliferations, focusing on chronic myeloid leukemia (CML) [@bib10]. CML accounts for 15--25% of all adult leukemias and is characterized by an abnormal proliferation of mature granulocytes and their precursors as well as by the fusion gene BCR-ABL1 [@bib11]. As mentioned in our editorial about the history of tyrosine kinases, the first targeted tyrosine-kinase inhibitor that succeeded as an FDA-approved drug was imatinib in 2001 for the treatment of CML and has since then massively improved therapy and patient life quality [@bib12].

The study consists in the comparison of complete blood counts and VCS data from newly diagnosed CML patients, CML patients under imatinib treatment, patients with high neutrophil counts, pregnant women and healthy controls. Compared to the benign controls, untreated CML patients exhibited indeed significantly higher mean neutrophil and monocyte volumes (MNV, MMV), higher mean lymphocyte scatter (MLS) as well as higher standard deviations of mean neutrophil volume and conductivity (MNV-SD, MNC-SD). Without the input of total leucocyte counts, untreated CML could be distinguished from benign neutrophilia notably *via* the combination of MNV and MNC-SD. Upon treatment by imatinib on the other hand, these values and several other parameters seemed to normalize, which suggests that monitoring their evolution in the course of therapy could serve as an indicator for treatment efficiency. Moreover, the combined analysis of the VCS data by two algorithmic approaches managed to discriminate untreated CML cases against all other groups.

As the authors point out, rather than supplanting an expert opinion in the case of a specific diagnostic conjecture, this type of analysis and many similar ones could be integrated without any extra cost or need for time and more samples into global routine automated health check-ups. Any detected anomaly would generate an immediate "electronic warning flag", subsequently prompting the medical personnel to issue further appropriate tests. Furthermore, aside from the diagnostic value, this would allow for a statistically valuable collection of standardized data on a multitude of conditions, which could in turn help to gain biological insights into both pathogenesis and treatment time course.
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### 30 years of tyrosine phosphorylation {#sec3.1.1}

At the occasion of the bestowal of the prestigious 2018 Tang Prize in Biopharmaceutical Science to Tony Hunter, Brian Druker and John Mendelsohn "for the discovery of protein tyrosine phosphorylation and tyrosine kinases as oncogenes, leading to successful targeted cancer therapies", Jau-Song Yu takes us in his editorial onto a captivating travel through 30 years of history of tyrosine phosphorylation [@bib13].

The story starts with the discovery of tyrosine phosphorylation by Tony Hunter\'s lab in 1979 and the ensuing realization that it is key to major transmembrane signal transmission mechanisms frequently hijacked by tumors [@bib14]. Immediately flagging them as potential anti-cancer targets, research subsequently focused on small molecule inhibitors of oncogenic tyrosine kinases (TK), but the path from bench to bedside proved to be long. Brian Druker\'s team was the first to succeed with the approval of imatinib for the treatment of chronic myelogenous leukemia (CML) in 2001 [@bib15]. In parallel, John Mendelsohn and his colleagues worked on the development of antibodies to block the tyrosine kinase signaling, an equally long but fruitful trail that led to the release of cetuximab for cancer colon therapy in 2004 [@bib16]. The search for specific TK inhibitors continues undamped, presently striving to integrate multi-omics and the concept of personalized medicine in order to optimize the patient\'s treatment response.
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### Risks and outcomes of *Clostridium difficile* infection in a hospital setting {#sec3.2.1}

*C. difficile* is a bad competitor - as long as a healthy microbiotum is in place, the pathogen is usually kept in check [@bib17]. However, once the latter is disrupted, as a consequence of lifestyle or medical treatment, *C. difficile* can cause persistent disease ranging from mild diarrhea to life-threatening pseudomembraneous colitis [@bib18]. Thereby it has successfully acquired the infamous title of number one hospital acquired infection (12,1%) and the global incidence of *C. difficile* infection (CDI) is on the rise [@bib19]. Facing the frequency of infection relapse, fecal microbiota transplantation might be sometimes the last hope for cure [@bib20]. In their study, Lee et al. aim to identify risk factors for CDI, the associated mortality rate and to put forward possible prevention methods [@bib21]. They observe that underlying peptic ulcer disease and previous use of gastric acid inhibitors or third generation cephalosporins for at least 3 days significantly correlate with CDI. Mortality was only linked to overall Charlson scores however. The authors strongly recommend to base CDI treatment rather on Charlson scores than CDI-specific parameters, as underlying diseases play an equally important role in the treatment outcome.

### Mean platelet volume measurements could improve the early diagnosis of acute coronary syndrome {#sec3.2.2}

Acute coronary syndrome (ACS) reflects the reduction in blood flow in the coronary arteries usually after atheroma rupture or erosion resulting in the formation of a thrombus [@bib22]. The direct consequence being malfunction and/or necrosis of the heart muscle, every minute counts in making the correct diagnosis and starting treatment [@bib23]. Currently, electrocardiogram (ECG) characteristics and cardiac Troponin I and T are the main, yet not foolproof, diagnostic checkpoints. Consequently, additional biomarkers that are fast and easy to obtain would be beneficial in order to avoid both under- and misdiagnoses. ACS is a consequence of atherothrombosis and the latter involves the activation of platelets, which in turn correlates with an increase in mean platelet volume (MPV) and immature platelet fraction (IPF). Here, Huang et al. interrogate the diagnostic value of these two parameters in confirming ACS [@bib24]. Indeed, according to a retrospect study, both are higher in ACS patients and MPV could be used as an independent predictor of ACS diagnosis.

### Description and trouble-shooting of ultrasonic motor-induced artifacts in magnetic resonance imaging {#sec3.2.3}

Combining magnetic resonance imaging (MRI) with robot-assisted interventions should improve accuracy, stability and sampling reproducibility targeting during surgery [@bib25]. However, the synergy is challenged by inherent features of the robot, such as actuators and sensors, which tend to interfere with the MRI instrument [@bib26]. Ultrasonic motors (USMs) are nonmagnetic devices optimized for the use in surgical robots [@bib27], [@bib28], yet some limitations due to various image artifacts still remain [@bib29]. In the present article, Shokrollahi et al. aim at identifying the type and origin of USM-caused MRI image artifacts and the means to minimize them [@bib30]. The authors observe signal voids, pileups, geometric distortions as well as zipper and motion artifacts. Aligning the motor shaft with the bore axis, decreasing slice thickness, augmenting bandwidth and ultra-short echo time sequences partially corrected several artifacts.

### Advanced ankylosing spondylitis patients display imbalanced loss of trunk muscle strength {#sec3.2.4}

Ankylosing spondylitis (AS) is an incurable auto-inflammatory systemic rheumatic disease with strong genetic association, notably the HLA-B27 genotype [@bib31], mainly affecting the joints of the spine and affecting up to 1,8% of the population. Progressing disease can lead to the ossification of the vertebrae and the fusion of the spine, severely impacting quality of life. Decrease of muscle mass and strength are other disease manifestations but also therapeutic targets.

Wang et al. search to characterize the trunk isometric strength and the ratio of flexor and extensor strength at varying trunk postures in AS patients at different disease stages [@bib32]. Patients of the most advanced AS stages displayed lowest isometric trunk muscle strength as well as greater loss in extensor than flexor muscle strength. Consequently, the authors recommend a strengthening program focusing on the extensor muscles.

### General endotracheal anesthesia is suitable for ERCP-assisted biliary stone removal {#sec3.2.5}

Endoscopic retrograde cholangiopancreatography (ERCP) is an invasive procedure combining upper gastrointestinal endoscopy and X-rays to treat narrowed or blocked bile and pancreatic ducts, for instance because of gallstones [@bib33]. Liang et al. investigate here *via* a retrospective study the safety, rate of success and possible complications of performing ERCP-assisted biliary stone extraction either with conscious, local sedation (NS) or under general endotracheal anesthesia (GET) [@bib34]. According to their results, the GET group had a higher success rate of complete stone extraction with smaller required rates of contrast injection but a slightly higher risk to develop pneumonia due to the tracheal intubation after the procedure. Preventive strategies could further lower the risk of the latter.
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